Mitomycin C and lonidamine as second-line treatment of advanced colorectal cancer patients.
Evaristo Maiello(Casa Sollievo della Sofferenza), Giuseppe Colucci(University of Basel), Domenico Galetta(Istituto Tumori Bari), Francesco Giotta(Istituto Tumori Bari), Antonio Testa(University of Palermo), Ferdinando Riccardi(Ospedale Antonio Cardarelli), Nicolo' Gebbia(Azienda Ospedaliera Universitaria Policlinico "Paolo Giaccone" di Palermo), Vittorio Gebbia(Università degli Studi di Enna Kore)
PubMed
December 11, 1996
Cited by 1
Related Papers
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
|The Lancet Oncology|2012|5.5k
Chemotherapy for Elderly Patients With Advanced Non-Small-Cell Lung Cancer: The Multicenter Italian Lung Cancer in the Elderly Study (MILES) Phase III Randomized Trial
|JNCI Journal of the National Cancer Institute|2003|795
Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial
|The Lancet Oncology|2019|617
First-Line Erlotinib Followed by Second-Line Cisplatin-Gemcitabine Chemotherapy in Advanced Non–Small-Cell Lung Cancer: The TORCH Randomized Trial
|Journal of Clinical Oncology|2012|234